# Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

> **NCT06184360** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2079 (actual)

## Conditions studied

- Neovascular (Wet) Age-related Macular Degeneration

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06184360
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-31
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-16
- **Target enrollment:** 2079 (ACTUAL)
- **Last updated:** 2023-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06184360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06184360, "Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06184360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*